ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0520

Combination Therapy of Mycophenolate Mofetil and Pirfenidone vs. Mycophenolate Alone: Results from the Scleroderma Lung Study III

Dinesh Khanna1, Cathie Spino2, Elana Bernstein3, Jonathan Goldin4, Donald Tashkin4, Michael roth4 and On Behalf of SLS III Investigators2, 1Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI, 3Columbia University, New York, NY, 4University of California Los Angeles, Los Angeles, CA

Meeting: ACR Convergence 2022

Keywords: clinical trial, interstitial lung disease, Systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Abstracts: Systemic Sclerosis and Related Disorders – Clinical I: Trials and Therapeutics

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Scleroderma Lung Study (SLS) II established mycophenolate mofetil (MMF) as an active therapy for scleroderma-related interstitial lung disease (SSc-ILD) and the need to consider background MMF in trial designs. SLS III envisioned an upfront combination therapy in which the rapid onset and anti-fibrotic effects of pirfenidone (PFD) would complement the delayed immunosuppressive and anti-inflammatory effects of MMF.

Methods: An investigator-initiated multi-center, double-blind, placebo (PLA)-controlled Phase II trial evaluated combination therapy (MMF+PFD vs MMF+PLA) in those with SSc-ILD. Key inclusion criteria were age≥18, SSc-ILD with symptoms (Mahler dyspnea index), FVC% ≤ 85% predicted, disease duration ≤7 yrs, and any ground glass opacity on HRCT. Subjects were randomized to each arm, stratified by site and prior MMF therapy (naïve, >0 to ≤3 months, and >3 months to 6 months) with a planned enrollment of 150. The primary endpoint was the change from baseline in the mean forced vital capacity % predicted (FVC%) over the course of the 18-month treatment period. Treatment differences were tested using linear mixed effects models for longitudinal endpoints and ANCOVA for HRCT endpoints measured at screening and 18 months, both adjusting for prior MMF therapy and efficacy measure at screening or baseline.

Results: 51 participants were randomized (76% naive; 14% ≤3 months MMF; 10% >3-6 months MMF) with 27 to MMF+PFD and 24 to MMF+PLA. Recruitment was prematurely stopped due to COVID-19 and the impact of prior drug treatment on eligibility. Table 1 details baseline characteristics. Overall, a similar magnitude of improvement in FVC% over 18 months occurred in both arms (2.24% MMF+PLA vs. 2.09% MMF+PFD; P=0.93) with a more rapid improvement noted in the MMF+PFD arm over 6 months (Figure 1). In addition, there were trends favoring the PFD arm in HRCT quantification of fibrosis (QLF) and interstitial lung disease (QILD) as well as in HAQ-DI, SGRQ-activity scale, and PROMIS-29 physical function scales, all meeting/exceeding minimally important differences (Table 2). 74.1% of subjects on MMF+PFD vs 29.2% on MMF+PLA had adverse events of special interest; the difference primarily related to gastrointestinal disorders (55.6% vs. 20.8%) and photosensitivity (14.8% vs 0%). 7 participants prematurely discontinued one or both study drugs, all in the MMF+PFD arm. There were no deaths.

Conclusion: Consistent with a primary hypothesis, upfront combination therapy (MMF+PFD) led to more rapid improvement in the FVC% (0-6 months) but with a similar overall improvement over 18 months as compared to MMF +PLA. Changes in HRCT outcomes and patient-reported outcomes tended to favor MMF+PFD. Side effects were similar to the published literature and more common with MMF+ PFD. Although the study was underpowered, it raises the question whether upfront MMF+PFD can lead to a more rapid improvement in FVC and greater impact on HRCT and patient-reported outcomes.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: D. Khanna, Boehringer Ingelheim, Genentech, Prometheus, Horizon, Chemomab, Talaris, Gesynta, Amgen, Acceleron, Actelion, Bayer, CSL Behring, Paracrine Cell Therapy, Mitsubishi Tanabe, Theraly, Eicos Sciences; C. Spino, None; E. Bernstein, Boehringer-Ingelheim, Kadmon, Pfizer; J. Goldin, MedQIA, LLC; D. Tashkin, Genentech; M. roth, Genentech; O. SLS III Investigators, None.

To cite this abstract in AMA style:

Khanna D, Spino C, Bernstein E, Goldin J, Tashkin D, roth M, SLS III Investigators O. Combination Therapy of Mycophenolate Mofetil and Pirfenidone vs. Mycophenolate Alone: Results from the Scleroderma Lung Study III [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/combination-therapy-of-mycophenolate-mofetil-and-pirfenidone-vs-mycophenolate-alone-results-from-the-scleroderma-lung-study-iii/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/combination-therapy-of-mycophenolate-mofetil-and-pirfenidone-vs-mycophenolate-alone-results-from-the-scleroderma-lung-study-iii/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology